Clinical Trial Update: Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated the safety, tolerability, efficacy, and pharmacokinetics/pharmacodynamics of three doses of BI 187004 over 28 days in adults with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BI 187004

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED